Short Interest in Coya Therapeutics, Inc. (NASDAQ:COYA) Rises By 123.4%

Coya Therapeutics, Inc. (NASDAQ:COYA) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 46,700 shares, a growth of 123.4% from the February 29th total of 20,900 shares. Based on an average daily volume of 92,200 shares, the short-interest ratio is presently 0.5 days. Currently, 0.4% of the company’s shares are short sold.

Coya Therapeutics Trading Up 2.8 %

NASDAQ COYA traded up $0.27 on Thursday, reaching $9.92. The stock had a trading volume of 122,922 shares, compared to its average volume of 95,219. The business has a 50 day moving average price of $8.06 and a 200 day moving average price of $6.40. Coya Therapeutics has a 1 year low of $3.21 and a 1 year high of $10.69. The company has a market capitalization of $99.50 million, a price-to-earnings ratio of -12.74 and a beta of 0.78.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of COYA. BlackRock Inc. acquired a new position in shares of Coya Therapeutics during the 1st quarter worth about $31,000. Geode Capital Management LLC acquired a new position in shares of Coya Therapeutics in the 2nd quarter worth approximately $238,000. Mirador Capital Partners LP bought a new stake in Coya Therapeutics during the 2nd quarter worth approximately $63,000. Citadel Advisors LLC bought a new stake in Coya Therapeutics during the 2nd quarter worth approximately $43,000. Finally, Worth Venture Partners LLC boosted its position in Coya Therapeutics by 6.3% in the 2nd quarter. Worth Venture Partners LLC now owns 146,493 shares of the company’s stock valued at $596,000 after buying an additional 8,735 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Chardan Capital lifted their price target on Coya Therapeutics from $11.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 20th.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.